SF4250

Purpose

To change how prescription drug prices are regulated in Minnesota by repealing older price-control provisions and adding new factors for evaluating drug costs, along with stronger disciplinary provisions for certain health professionals and new enforcement tools. The bill seeks to shift focus from explicit price caps to cost review, transparency, and professional纪律 (discipline) mechanisms, while removing some existing notice and withdrawal requirements for drugs.

Key terms and concepts carried forward or added

• Excessive price increase
• Generic or offpatent drug
• Wholesale acquisition cost
• Registered agent and office within the state
• Consumer Price Index (CPI)
• FDA-labeled indications
• Cost statements and drug cost investigations
• Civil penalties and enforcement
• Private right of action
• Withdrawal of drug from sale or distribution
• Price provisions and related enforcement (even where repealed, some references remain in enforcement provisions)

Main provisions

• Repeal of price increase restrictions

  • Repeals Minnesota Statutes sections 62J.841, 62J.842, 62J.843, 62J.844, 62J.845, and 62J.846. This removes the prior formal prohibition on excessive price increases and related notice or withdrawal provisions.

• Conforming amendments to cost review (new framework for evaluating drug costs)

  • Amends section 62J.91, subdivision 2, to allow the board to consider a range of factors when reviewing prescription drug costs, including:
  • The price at which the drug has been and will be sold in the state
  • Manufacturer price concessions, discounts, rebates, and patient assistance
  • The cost to group purchasers (aligned with FDA-labeled indications and standard medical practice)
  • Measures of patient access (e.g., cost-sharing)
  • Any prior findings that a price increase was excessive
  • Information provided by manufacturers and other relevant factors

• Expanded professional discipline and penalties (for licensees and registrations)

  • Amends Minnesota Statutes 2024 section 151.071, subdivision 1 to broaden disciplinary tools, including:
  • Denial, non-renewal, revocation, suspension, or limitations on licenses/registrations
  • Imposition of conditions or training requirements
  • Civil penalties (up to $10,000 per violation; up to $25,000 for violations tied to sections 62J.842)
  • Possible combinations of actions and conditions to safeguard practice
  • Subdivision 2 and 3 outline specific grounds for disciplinary action, including:
  • Failure to meet qualifications or satisfy licensing requirements
  • Fraud or cheating in licensing processes
  • Conduct subverting licensing examinations
  • Conviction of felonies reasonably related to the practice
  • Delays or actions related to licensing for felonies or pending charges
  • Prior disciplinary actions in other states or jurisdictions, or failure to report them
  • Unethical, unprofessional, or unsafe conduct
  • Violations of board orders or relevant laws/rules
  • Involvement in practice while license/registration is lapsed or nonrenewed
  • Other grounds such as aiding or abetting unlicensed practice
  • Specific prohibitions related to practice settings, patient safety, or professional conduct
  • Additional grounds cover issues across pharmacies, facilities, and controlled-substance researchers, including treatment-related conditions that affect safe practice and the need for supervision or credentialing safeguards

• Registration and enforcement improvements

  • Section 62J.843: Requires manufacturers that sell, distribute, or offer for sale any generic or offpatent drug in Minnesota to maintain a registered agent and a state-based office.
  • Section 62J.844: Enforcement framework
  • Notification: Commissioner of health must notify manufacturers and the attorney general of price increases believed to violate 62J.842 (even though the repeal changes the section, the enforcement framework remains in this provision).
  • Drug cost statement: Manufacturers must submit a drug cost statement within 45 days, detailing production costs, cost-change timing, and other relevant information.
  • Investigation and court relief: Attorney General may investigate; courts can issue orders to compel statements, review pricing, recover costs, and impose civil penalties (up to $10,000 per day; up to $25,000 per violation for 62J.842-related issues). Revenues from violations may be deposited into a state fund for consumer cost-reduction initiatives.
  • Private right of action: Individuals harmed by violations may pursue actions that are for the public's benefit.

• Prohibition on drug withdrawal (reframed)

  • Section 62J.845 (as part of repealed provisions) previously prohibited withdrawing generic or offpatent drugs to avoid price restrictions and imposed a 90-day notice requirement and a $500,000 penalty for noncompliance. The text indicates withdrawal-related restrictions remain within the amended framework, with penalties for noncompliance.

• Severability

  • Section 62J.846 preserves severability so that invalid provisions do not affect the rest of the sections.

Significant changes to existing law

• Price regulation shift

  • The bill eliminates the explicit prohibitions on excessive price increases (previous 62J.841–62J.846) and replaces them with a cost-review framework and enforcement measures focused on transparency and penalties rather than direct price caps.

• New cost-review factors

  • The board gains explicit authority to consider a broad set of cost and access factors when evaluating prescription drug costs, including CPI-adjusted pricing, discounts, patient assistance, and access measures.

• Expanded licensing discipline

  • A broader set of grounds for disciplining licensees and registrants, with enhanced civil penalties and potential restrictions or conditions on practice, including actions related to ethics, professional conduct, and safety.

• Compliance and enforcement mechanisms

  • Establishes a formal process for notifying manufacturers, obtaining drug cost statements, and pursuing enforcement through the attorney general and courts, with the possibility of significant penalties and revenue remittance to a state fund.

• Manufacturer registration requirement

  • Requires manufacturers to maintain a registered agent and a Minnesota office, increasing in-state presence for regulatory oversight.

• Withdrawal-related penalties

  • Strengthens the potential penalties for withdrawing a drug to avoid price regulation, reinforcing the state’s ability to respond to price-related concerns.

Potential implications

• For consumers

  • Shifts away from automatic price caps toward price review and transparency, with potential for penalties if price increases are deemed excessive under the new framework. May increase scrutiny of drug pricing practices.

• For manufacturers and distributors

  • Increased regulatory scrutiny, mandatory in-state presence, and potential penalties for price actions and withdrawal behaviors. More reporting and documentation requirements.

• For health professionals and pharmacies

  • Broader grounds for disciplinary action and civil penalties, with emphasis on ethics, safety, and compliance with board rules.

• For state agencies

  • More tools to monitor and address drug pricing, including investigations, court orders, and remittance of penalties into a state fund aimed at reducing consumer drug costs.

Relevant terms

• excessive price increase
• generic or offpatent drug
• wholesale acquisition cost (WAC)
• CPI (Consumer Price Index)
• FDA-labeled indications
• registered agent and office within the state
• drug cost statement
• price concessions, discounts, rebates, patient assistance
• patient access
• civil penalties
• enforcement by attorney general and courts
• private right of action
• withdrawal from sale or distribution
• disciplinary actions (license denial, suspension, revocation, conditions)
• practice and conduct grounds (unethical, unprofessional, safety-related)

Relevant Terms - excessive price increase - wholesale acquisition cost - generic or offpatent drug - registered agent - Consumer Price Index (CPI) - FDA-labeled indications - drug cost statement - civil penalty - enforcement - private right of action - withdrawal notice - disciplinary action - professional conduct - license suspension/revocation